Aug 182017

Liquid biopsy for cancer
Credit: Reprinted with permission from Victor Velculescu et al., Science Translational Medicine 2017

In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to accurately identify more than half of 138 people with relatively early-stage colorectal, breast, lung and ovarian cancers. The test, the scientists say, is novel in that it can distinguish between DNA shed from tumors and other altered DNA that can be mistaken for cancer biomarkers.

A report on the research, performed on blood and tumor tissue samples from 200 people with all stages of cancer in the U.S., Denmark and the Netherlands, appears in the Aug. 16 issue of Science Translational Medicine.

“This study shows that identifying cancer early using DNA changes in the blood is feasible and that our high accuracy sequencing method is a promising approach to achieve this goal,” says Victor Velculescu, M.D., Ph.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center.

Blood tests for cancer are a growing part of clinical oncology, but they remain in the early stages of development. To find small bits of cancer-derived DNA in the blood of cancer patients, scientists have frequently relied on DNA alterations found in patients’ biopsied tumor samples as guideposts for the genetic mistakes they should be looking for among the masses of DNA circulating in those patients’ blood samples.

To develop a cancer screening test that could be used to screen seemingly healthy people, scientists had to find novel ways to spot DNA alterations that could be lurking in a person’s blood but had not been previously identified.

“The challenge was to develop a blood test that could predict the probable presence of cancer without knowing the genetic mutations present in a person’s tumor,” says Velculescu.

The goal, adds Jillian Phallen, a graduate student at the Johns Hopkins Kimmel Cancer Center who was involved in the research, was to develop a screening test that is highly specific for cancer and accurate enough to detect the cancer when present, while reducing the risk of “false positive” results that often lead to unnecessary overtesting and overtreatments.

The task is notably complicated, says Phallen, by the need to sort between true cancer-derived mutations and genetic alterations that occur in blood cells and as part of normal, inherited variations in DNA.

As blood cells divide, for example, Velculescu says there is a chance these cells will acquire mistakes or mutations. In a small fraction of people, these changes will spur a blood cell to multiply faster than its neighboring cells, potentially leading to pre-leukemic conditions. However, most of the time, the blood-derived mutations are not cancer-initiating.

His team also ruled out so-called “germline” mutations. While germline mutations are indeed alterations in DNA, they occur as a result of normal variations between individuals, and are not usually linked to particular cancers.

To develop the new test, Velculescu, Phallen and their colleagues obtained blood samples from 200 patients with breast, lung, ovarian and colorectal cancer. The scientists’ blood test screened the patients’ blood samples for mutations within 58 genes widely linked to various cancers.

Overall, the scientists were able to detect 86 of 138 (62 percent) stage I and II cancers.   More specifically, among 42 people with colorectal cancer, the test correctly predicted cancer in half of the eight patients with stage I disease, eight of nine (89 percent) with stage II disease, nine of 10 (90 percent) with stage III and 14 of 15 (93 percent) with stage IV disease. Of 71 people with lung cancer, the scientists’ test identified cancer among 13 of 29 (45 percent) with stage I disease, 23 of 32 (72 percent) with stage II disease, three of four (75 percent) with stage III disease and five of six (83 percent) with stage IV cancer. For 42 patients with ovarian cancer, 16 of 24 (67 percent) with stage I disease were correctly identified, as well as three of four (75 percent) with stage II disease, six of eight (75 percent) with stage III cancer and five of six (83 percent) with stage IV disease. Among 45 breast cancer patients, the test spotted cancer-derived mutations in two of three (67 percent) patients with stage I disease, 17 of 29 (59 percent) with stage II disease and six of 13 (46 percent) with stage III cancers.

They found none of the cancer-derived mutations among blood samples of 44 healthy individuals.

Despite these initial promising results for early detection, the blood test needs to be validated in studies of much larger numbers of people, say the scientists.

Velculescu and his team also performed independent genomic sequencing on available tumors removed from 100 of the 200 patients with cancer and found that 82 (82 percent) had mutations in their tumors that correlated with the genetic alterations found in the blood.

The Johns Hopkins-developed blood test uses a type of genomic sequencing the researchers call “targeted error correction sequencing.” The sequencing method is based on deep sequencing, which reads each chemical code in DNA 30,000 times. “We’re trying to find the needle in the haystack, so when we do find a DNA alteration, we want to make sure it is what we think it is,” says Velculescu.

Such deep sequencing, covering more than 80,000 base pairs of DNA, has the potential to be very costly, but Velculescu says sequencing technology is becoming cheaper, and his research team may eventually be able to reduce the number of DNA locations they screen while preserving the test’s accuracy.

He says the populations that could benefit most from such a DNA-based blood test include those at high risk for cancer including smokers — for whom standard computed tomography scans for identifying lung cancer often lead to false positives — and women with hereditary mutations for breast and ovarian cancer within BRCA1 and BRCA2 genes.

Learn more: Scientists Develop Blood Test That Spots Tumor-Derived DNA in People With Early-Stage Cancers


The Latest on: Cancer detection
  • We're getting better at screening for cancer, and that could be a problem
    on January 20, 2018 at 6:53 am

    “They’re not just a person anymore, they’re a patient. There’s a tremendous worry that comes with a cancer diagnosis.” And patients, she says, have to start making choices about whether or not to undergo treatments, often chemotherapy, that have ... […]

  • CancerSEEK to detect cancer with a blood test
    on January 20, 2018 at 6:23 am

    The aim of the test, CancerSEEK, is to catch the disease early and save lives. Scientists at John Hopkins University in Baltimore analysed more than 1,000 cancer patients who had shown symptoms of cancer, to see whether this new test would accurately ... […]

  • We Might Finally Be Able to Detect Cancer Through a Simple Blood Test
    on January 19, 2018 at 8:59 pm

    Many cancer patients don’t receive a diagnosis until their disease has progressed too far to treat very easily with surgery alone. By the time symptoms have become apparent, tumors have often metastasized to other parts of the body, which means turning ... […]

  • A New Blood Test May Be Able to Detect Early Stage Cancer
    on January 19, 2018 at 6:49 pm

    Imagine walking into a doctor’s office for a simple blood test—and catching an early sign of cancer that saves your life. That might become a reality soon, thanks to new research published in the journal Science. While this may sound like something ... […]

  • This blood test may be able to detect 8 types of cancer, study says
    on January 19, 2018 at 10:00 am

    (CNN)Scientists have made progress on developing an experimental blood test that could detect many types of cancer in their early stages, and possibly even their locations in the body. The noninvasive blood test was shown to detect the presence of common ... […]

  • A 23-year-old local news anchor details her harrowing cancer diagnosis
    on January 19, 2018 at 12:49 am

    When Natasha Verma noticed a lump on her collarbone last summer, she thought it was a muscle sprain. The NBC Boston anchor, 23, frequently visited the gym when she wasn’t working on the station’s morning news broadcast, and figured she had ... […]

  • Cancer Detection: New Blood Test, CancerSeek, Can Spot 8 Varieties
    on January 18, 2018 at 10:35 pm

    In a major breakthrough, scientists have devised a blood test that can detect eight of the most common types of cancer. A team of scientists at John Hopkins University, who published the study in journal Science on Thursday, said the test could be ... […]

  • Life-Saving Early Cancer Detection Could Be Vastly Improved With New Blood Test
    on January 18, 2018 at 11:59 am

    Finding out if you have one of eight cancers could someday be as simple as having your blood drawn, thanks to a new test. For five of these cancers, the test, called CancerSEEK, would be the first-ever screening of its kind to become available. It could ... […]

  • Cancer Diagnosis from a Blood Draw? Liquid Biopsies Are Still a Dream
    on January 18, 2018 at 11:04 am

    Nick Papadopoulos tracks down tumors for a living. Not with X-rays or CT scans, but with DNA. The oncologist and director of translational genetics at the Johns Hopkins Kimmel Cancer Center has spent decades uncovering the unique sets of mutations that ... […]

  • This new blood test can detect early signs of 8 kinds of cancer
    on January 17, 2018 at 11:00 pm

    Scientists have developed a noninvasive blood test that can detect signs of eight types of cancer long before any symptoms of the disease arise. The test, which can also help doctors determine where in a person’s body the cancer is located, is called ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: